CGT

654개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved654 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleBeijing BiotechPhase 2

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

Malignant Pleural Mesotheliomas · Malignant Pleural Mesotheliomas

#MalignantPleuralMesotheliomas#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

EGFR/ B7H3-positive Advanced Lung Cancer; EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSeattle Children's HospitalPhase 1

EGFR806-specific chimeric antigen receptor (CAR, EGFR806-specific chimeric antigen receptor, EGFR806-specific chimeric antigen receptor (CAR) T cell)

Central Nervous System Tumor, Pediatric; Glioma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

EPCAM CAR-T (EPCAM CAR-T)

Advanced Hepatocellular Carcinoma; Advanced Colorectal Cancer · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Boren HospitalPhase 1

Efficacy of LCAR-T2C CAR-T cells (Efficacy of LCAR-T2C CAR-T cells)

T Cell Lymphoma; T-cell Leukemia · T Cell Lymphoma

#TCellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells (Engineering of chimeric antigen receptors targeting CD19 in allogeneic T cells)

Difficult to Treat Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleTCRCure Biopharma Ltd.Phase 1

Enhanced ALPP CAR-T treatment (Enhanced ALPP CAR-T treatment)

Solid Tumor · Solid Tumor

#SolidTumor#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-DCs (EphA2-targeted CAR-DCs)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

EphA2-targeted CAR-T Cells (EphA2-targeted CAR-T Cells)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleAMERICAN ORGAN TRANSPLANT AND C…Phase 2

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

End-Stage Renal Disease; End Stage Renal Disease on Dialysis · End-Stage Renal Disease

#End-StageRenalDisease#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSolving Kids' CancerPhase 1

Ex vivo Expanded and Activated Haploidentical Donor NK Cells (Ex vivo Expanded and Activated Haploidentical Donor NK Cells)

Neuroblastoma; Relapsed Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Phase 1

Experimental: CAR-T cells Infusion (Experimental: CAR-T cells Infusion)

Multiple Myeloma; Primary Plasma Cell Leukemia · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleUTC Therapeutics Inc.Phase 1

FAST LACO-Stim CDH17 CAR-T (FAST LACO-Stim CDH17 CAR-T)

Biliary Tract Cancer; Colorectal Carcinoma · Biliary Tract Cancer

#BiliaryTractCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

FGFR4-CAR T Cells (FGFR4-CAR T Cells)

Rhabdomyosarcoma · Rhabdomyosarcoma

#Rhabdomyosarcoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

FL33-03 CAR-T therapy (FL33-03 CAR-T therapy)

Refractory/Relapsed Acute Myeloid Leukaemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleFate TherapeuticsPhase 1

Allogenic CAR NK cells with BCMA expression (FT576, FT576 (Allogenic CAR NK cells with BCMA expression))

Multiple Myeloma; Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^8 cells per dose (FT836 CAR T cells, FT836 CAR T cells (1 x 10^8 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

3 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (3 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

23 / 33 pages

← PreviousNext →